UROLIFT® BPH Relief. In Sight.™

Commonly Billed Codes 2021

Diagnosis Coding	
ICD-10 Diagnosis Coding	
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms (LUTS)

Physician Coding: All Sites of Service			
CPT®	**Description**	**OFFICE National Unadjusted Allowed Amount**	**FACILITY National Unadjusted Allowed Amount**
52441	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant	$1,433	$212
+52442	Each additional permanent adjustable transprostatic implant (List separately in addition to code for primary procedure)	$1,020	$52

Medicare Physician Fee Schedule, National Unadjusted RVUs							
CPT Code	**Global Period**	**Work RVUs**	**PE RVUs FAC**	**PE RVUs Non-FAC**	**Malpract RVUs**	**Total RVUs FAC**	**Total RVUs Non-FAC**
52441	000	4.00	1.62	36.62	0.46	6.08	41.08
+52442	zzz	1.01	0.35	28.12	0.13	1.49	29.26

Facility Coding: Hospital Outpatient or Ambulatory Surgery Center (ASC)		Hospital			ASC	
HCPCS	**Description**	**APC**	**APC Allowed Amount**	**SI**	**Allowed Amount**	**SI**
C9739	Cystourethroscopy, with insertion of transprostatic implant; 1 to 3 implants	5375	$4,414	J1†	$3,407	J8††
C9740	Cystourethroscopy, with insertion of transprostatic implant; 4 or more implants	5376	$8,258	J1†	$7,052	J8††

Device Code - Hospital Outpatient Only	
HCPCS	**Description**
L8699	Prosthetic implant, not otherwise specified (each implant)

Facility Coding: Alternative Coding for Some Commercial Plans*		Hospital	ASC
CPT®	**Description**	**APC Allowed Amount**	**Allowed Amount**
52441	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant	Insurer Priced	Insurer Priced
+52442	Each additional permanent adjustable transprostatic implant (List separately in addition to code for primary procedure)	Insurer Priced	Insurer Priced

**While most insurers follow Medicare coding guidelines, some insurers may prefer the use of the CPT codes normally used for physician billing. Confirm preferred coding with each commercial insurer.*

†Comprehensive APC; Payment for all adjunctive services reported on the same claim is packaged into payment for the primary service.

†† Device-intensive procedure; paid at adjusted rate.

Rates referenced in this guide do not reflect sequestration adjustments which are automatic reductions in federal spending that will result in a 2% across-the-board reduction to all Medicare rates as of April 1, 2013. Quoted rates also do not reflect payment adjustments related to quality of and/or meaningful use.

Disclaimer: The information contained in this document was obtained from third-party sources, and publicly available information. The content is informational only and is subject to change without notice. Nothing herein constitutes either medical, legal, coverage, coding, payment, or reimbursement advice or any statement, promise or guarantee of payment. NeoTract, Inc. makes no representations or warranties that this information is accurate, complete, and/or all-inclusive. The health care provider/user is solely responsible for determining appropriate treatment for the patient based on the unique medical needs of each patient and the independent judgment of the provider. It is also the responsibility of the provider to determine payer appropriate coding, medical necessity, site of service, documentation requirements and payment levels and to submit appropriate codes, modifiers and charges for services rendered. Although NeoTract, Inc. (through its engagement with data service providers and others) has made reasonable efforts to provide information that is accurate, complete, and current at the time of its issue, it is recommended that you consult your legal counsel, reimbursement/compliance advisor and/or payer organization(s) for confirmation of information and/or interpretation of payer-specific coding, coverage and payment expectations.

NeoTract, Inc. encourages providers to submit claims for services that are appropriately and accurately consistent with FDA clearance and approved labeling and does not promote the use of its products outside their FDA cleared labeling.

UROLIFT® SYSTEM REIMBURSEMENT SUPPORT

844.516.5966 | uroliftreimbursement@Teleflex.com

- All payment levels reflect 2021 Medicare national unadjusted payment rates; payment levels may vary geographically
- Department of Health and Human Services, Centers for Medicare & Medicaid Services. CMS-1734-F: CY 2021. Revisions to Payment Policies under the Physician Fee Schedule and Other Revisions to Medicare Part B. 2 December 2020. Allowed amounts are calculated with a conversion factor of $34.8930.
- Department of Health and Human Services, Centers for Medicare & Medicaid Services. CMS-1736-FC: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems – Final Rule with Comment Period and CY2021 payment rates.
- With exception of "add-on" coding, multiple procedures furnished during the same operative session may be discounted.
- CPT® codes and descriptions are copyright 2020 American Medical Association (AMA). All rights reserved. CPT® is a registered trademark of the American Medical Association.

neotract® | Teleflex®
INTERVENTIONAL UROLOGY